[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345019-105":59,"doc-detail-345019-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-g6pd-glucose-6-phosphate-dehydrogenase-as-a-biomarker-of-therapeutic-vulnerability-in-renal-cell-carcinoma","Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma","","Renal cell carcinoma (RCC) is the most common kidney cancer, with rising global incidence. Despite progress using VEGF-targeted tyrosine kinase inhibitors and immunotherapies, therapeutic resistance continues to restrict durable benefit, making biomarkers of tumor aggressiveness and treatment vulnerability urgently needed. This study assesses G6PD gene and protein expression in 121 RCC samples using immunohistochemistry and functional in vitro experiments. Functional assays using G6PDi-1 and anti-VEGF cabozantinib/lenvatinib indicate G6PD-dependent vulnerability in RCC models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-g6pd-glucose-6-phosphate-dehydrogenase-as-a-biomarker-of-therapeutic-vulnerability-in-renal-cell-carcinoma/345019/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-g6pd-glucose-6-phosphate-dehydrogenase-as-a-biomarker-of-therapeutic-vulnerability-in-renal-cell-carcinoma/345019.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why target G6PD in renal cell carcinoma?","Question",{"text":112,"@type":113},"G6PD is linked to altered energy metabolism in tumor cells and has been associated with multiple cancer types, motivating its evaluation as a biomarker and therapeutic vulnerability marker in RCC.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was G6PD expression measured in this study?",{"text":117,"@type":113},"G6PD gene and protein expression were evaluated in 121 RCC samples, with immunohistochemistry used to support expression differences across tumor types and pathological features.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the functional experiments suggest about treatment vulnerability?",{"text":121,"@type":113},"In vitro experiments with G6PDi-1 and VEGF inhibitors showed that G6PDi-1 had stronger effects on 786-O cells, impacting viability and other measures, while G6PD dependency differed across datasets, supporting G6PD as a potential biomarker and therapeutic target.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345019,1790194579,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Article  \nTargeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma  \nDaniel Pinheiro Ferreira 1,†, Ana Carolina Souza Mizael 2,3,†, Julia Victória Bonifácio Cabrieira 2,3, Rafaela Viviane Neves Silva 3, Liliane Silvano Araújo 3, Crislaine Aparecida Silva 3, Karen Bento Ribeiro 1, Adilha Misson Rua Michelleti 4, Juliana Reis Machado 2,3 and Régia Caroline Peixoto Lira 2,3, *  \nAcademic Editor: Giuseppe Lucarelli  \nReceived: 21 January 2026  \nRevised: 2 March 2026  \nAccepted: 12 March 2026  \nPublished: 20 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Clinics Hospital, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil; [daniel.uro@hotmail.com](daniel.uro@hotmail.com) (D.P.F.); [kkarenbento@yahoo.com.br](kkarenbento@yahoo.com.br) (K.B.R.)  \n2 Department of Pathology, Genetics and Evolution, Universidade Federal do Triângulo Mineiro,  \nUberaba 38025-015, Brazil; [anacarol.acm36@gmail.com](anacarol.acm36@gmail.com) (A.C.S.M.); [julia.vbonifacioc@gmail.com](julia.vbonifacioc@gmail.com) (J.V.B.C.); [juliana.machado@uftm.edu.br](juliana.machado@uftm.edu.br) (J.R.M.)  \n3 Kidney Research Center, Universidade Federal do Triângulo Mineiro, Uberaba 38025-015, Brazil; [rafaelaviviane912@gmail.com](rafaelaviviane912@gmail.com) (R.V.N.S.); [liliane.araujo@uftm.edu.br](liliane.araujo@uftm.edu.br) (L.S.A.); [crislaine.silva@uftm.edu.br](crislaine.silva@uftm.edu.br) (C.A.S.)  \n4 Department of Clinical Surgery, Universidade Federal do Triângulo Mineiro, Uberaba 38025-440, Brazil; [adilha.micheletti@uftm.edu.br](adilha.micheletti@uftm.edu.br)  \n* Correspondence: [regia.fusco@uftm.edu.br](regia.fusco@uftm.edu.br); Tel.: +55-34-3700-6486 † These authors contributed equally to this work.  \nAbstract  \nRenal cell carcinoma (RCC) is the most common kidney cancer, with increasing global incidence. Despite advances with VEGF-targeted tyrosine kinase inhibitors (TKIs) and immunotherapies, therapeutic resistance remains frequent, limiting long-term benefits. This highlights the need for potential biomarkers of tumor aggressiveness and therapeutic candidates, such as glucose-6-phosphate dehydrogenase (G6PD), whose altered expression has been associated with several cancers. We evaluated G6PD gene and protein expression in 121 RCC samples through immunohistochemistry and assessed functional role in vitro approaches. 786-O and ACHN cells were treated with the inhibitor G6PDi-1 and the anti-VEGF cabozantinib/lenvatinib. G6PD mRNA levels were higher in tumors than in non-neoplastic tissues, indicating shorter overall survival in clear cell (ccRCC) and papillary (pRCC) subtypes. Immunolabeling confirmed a higher expression in pRCC and associations with pathological features. CRISPR and RNAi datasets revealed a stronger G6PD dependency in the ccRCC. A high gene expression was observed in lenvatinib non-responder cell lines, and DepMap dose–response curves indicated modest responses to VEGF inhibitors. In vitro, ACHN was more sensitive to VEGF inhibition, particularly cabozantinib, whereas G6PDi-1 had stronger effects in 786-O, impairing viability, migration, and clonogenic capacity. Our findings support G6PD as a biomarker of tumor aggressiveness and G6PDi-1 as a potential therapeutic in RCC models.  \nKeywords: G6PD; renal cell carcinoma; tumor aggressiveness; therapeutic target  \n1. Introduction  \nRenal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 2–3% of all cancer diagnoses [1] . The clear cell histological subtype (ccRCC) is the most common, comprising 75–80% of cases, followed by papillary (pRCC) and chromophobe RCC (chRCC) . Prognosis is based on clinical and pathological features, including TNM  \nstaging, tumor size, Fuhrman grade, necrosis, and histological subtype. Despite","cbCaiasDMCxz7CdX","https://ap.wps.com/l/cbCaiasDMCxz7CdX","pdf",3095464,16,"English","# Abstract\n# Introduction","[{\"question\":\"Why target G6PD in renal cell carcinoma?\",\"answer\":\"G6PD is linked to altered energy metabolism in tumor cells and has been associated with multiple cancer types, motivating its evaluation as a biomarker and therapeutic vulnerability marker in RCC.\"},{\"question\":\"How was G6PD expression measured in this study?\",\"answer\":\"G6PD gene and protein expression were evaluated in 121 RCC samples, with immunohistochemistry used to support expression differences across tumor types and pathological features.\"},{\"question\":\"What do the functional experiments suggest about treatment vulnerability?\",\"answer\":\"In vitro experiments with G6PDi-1 and VEGF inhibitors showed that G6PDi-1 had stronger effects on 786-O cells, impacting viability and other measures, while G6PD dependency differed across datasets, supporting G6PD as a potential biomarker and therapeutic target.\"}]","Targeting G6PD (Glucose-6-Phosphate Dehydrogenase) as a Biomarker of Therapeutic Vulnerability in Renal Cell Carcinoma | PDF",1790056240,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/496e2f137e77eadbe6abe337a3e8b570.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b9e5119c1bff55e86a8e17773513c69e.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/470a3631096d07bf58372bea90eda4ba.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bb25343bdf3ada16f5d475d3fc26c4b.webp",980,1385]